Abstract:Background Adverse outcomes including myocardial infarction and stroke render coronary artery disease (CAD) a leading cause of death worldwide. Biomarkers that predict such adversity enable closer medical supervision and opportunities for improved outcomes. Methods and results We present a study of genome-wide DNA methylation profiling in 933 CAD patients with up to 13 years of clinical follow-up. We discovered 115 methylation sites associated with poor prognosis and inferred that cellular senescence, inflammation, and high-density lipoprotein mediated the adversity. We built succinct prognostic models combining a few methylation sites and clinical features, which could stratify patients of different risks. Furthermore, we assessed genetic regulation of the differential methylation by interrogating QTL effects. Prognostic genes such as FKBP5 , UBE2E2 and AUTS2 appeared recurrently in various analyses and were validated in patients of myocardial infarction and stroke. Conclusions Our study provides prognostic models for clinical application and revealed methylation biomarkers and mechanisms of CAD adverse outcomes. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was supported by the National Natural Science Foundation of China (No. 82274016, 32270626, 81872934), the Key-Area Research and Development Program of Guangdong Province, China (No. 2019B020229003), Greater Bay Area Research Institute of Precision Medicine (Guangzhou) Research Grants (I0005, R2001), National key research and development program (No. 2017YFC0909301) and the Science and Technology Program of Guangzhou (No. 2023B03J1251). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Medical Research Ethics Committee of Guangdong Provincial People's Hospital gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Gene regulatory elements were obtained from ENCODE5 catalog (). Enhancer-gene predictions by the ABC models in 131 biosamples were obtained from the ENGREITZ LAB (). CpG sites associated with diseases and traits were download from EWAS Catalog () and EWAS Atlas (). meQTL summary statistic data were obtained from Pan-mQTL (). eQTL summary statistics were derived from eQTLGen (). Single-nuclei RNA sequencing data of MI patients were available from Zenodo data archive (). Blood derived bulk RNA sequencing data were obtained from GEO database (GSE61144 and GSE16561). Calculation of DNA methylation age of GrimAge, Hannum clock, Hovath clock, and PhenoAge were performed by DNA Methylation Age Calculator ().

Blood DNA Methylation Sites Predict Death Risk in a Longitudinal Study of 12, 300 Individuals

Integrative analysis of clinical and epigenetic biomarkers of mortality

DNA methylation age of blood predicts all-cause mortality in later life

Blood Leukocyte DNA Methylation Predicts Risk of Future Myocardial Infarction and Coronary Heart Disease

Blood DNA Methylation Prospectively Predicts Mortality in Former and Current Smokers in the COPDGene Study

Epigenetic prediction of complex traits and death

Genome-wide association studies identify 137 loci for DNA methylation biomarkers of ageing

DNA Methylation Predicts Adverse Outcomes of Coronary Artery Disease

Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging

NMR metabolomics-guided DNA methylation mortality predictors

Comparative Validation of an Epigenetic Mortality Risk Score with Three Aging Biomarkers for Predicting Mortality Risks among Older Adult Males

DNA methylation GrimAge strongly predicts lifespan and healthspan

DNA Methylation-Based Biomarkers of Age Acceleration and All-Cause Death, Myocardial Infarction, Stroke, and Cancer in Two Cohorts: the NAS, and KORA F4

Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease

Association of Cardiovascular Health Through Young Adulthood with Genome-Wide DNA Methylation Patterns in Midlife: the CARDIA Study

Blood DNA Methylation Signature for Incident Dementia: Evidence from Longitudinal Cohorts

DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes

DNA Methylation Signatures of Cardiovascular Health Provide Insights into Diseases

Comparative validation of three DNA methylation algorithms of ageing and a frailty index in relation to mortality: results from the ESTHER cohort study

Abstract MP22: Plasma Metabolomic Profiles Associated With Mortality and Longevity in a Prospective Study of 13,401 Individuals

DNA Methylation-Based Estimator of Telomere Length